Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 32, Issue 2, 2003, Pages 161-169

  Coletti, Anne S ^a   Heagerty, Patrick ^b   Sheon, Amy R ^c   Gross, Michael ^d   Koblin, Beryl A ^e   Metzger, David S ^f   Seage III, George R ^g  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d National Institute of Allergy and Infectious Diseases   (United States)

^e NEW YORK BLOOD CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

High risk populations; HIV; HIV vaccines; Informed consent; Randomized trial

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ETHNIC GROUP; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RACE; RANDOMIZATION; SOCIOECONOMICS; UNITED STATES;

EID: 0037321668     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200302010-00008     Document Type: Article

References (43)

1. Beecher HK. Ethics and clinical research. N Engl J Med 1966;274:1354-60.
2. Gray BH. Human subjects in medical experimentation. New York: Wiley, 1975.
3. Ad Hoc Advisory Panel. Final report on the Tuskeegee Syphilis Study. Washington, DC: US Government Printing Office, 1973:5-15.
4. Howard JM, DeMets D, the BHAT Research Group. How informed is informed consent? The BHAT experience. Control Clin Trials 1981;2:287-303.
5. Cancer Research Campaign Working Party in Breast Conservation. Informed consent: ethical, legal, and medical implications for doctors and patients who participate in randomised clinical trials. BMJ 1983;286:1117-21.
6. Schultz AL, Pardee GP, Ensinck JW. Are research subjects really informed? West J Med 1975;123:76-80.
7. Lynöe N, Sandlund M, Dahlqvist G, et al. Informed consent: study of the quality of information given to participants in a clinical trial. BMJ 1991;303:610-3.
8. Applebaum PS, Roth LH, Lidz CW, et al. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep 1987;April:20-4.
9. Epstein LC, Lasagna L. Obtaining informed consent: form or substance. Arch Intern Med 1969;123:682-8.
10. Advisory Committee on Human Radiation Experiments. Final report. Washington, DC: US Government Printing Office, 1995.
11. Benson PR, Roth LH, Winslade WJ. Informed consent in psychiatric research: preliminary findings from an ongoing investigation. Soc Sci Med 1985;20:1331-41.
12. MacKillop WJ, Johnston P. Ethical problems in clinical research: the need for empirical research studies of the clinical trials process. J Chron Dis 1986;39:177-88.
13. Taub HA. Comprehension of informed consent for research: issues and directions for future studies. IRB 1986;November-December:7-10.
14. Stanley B, Sieber JE, Melton GB. Empirical studies of ethical issues in research: a research agenda. Am Psychol 1987;42:735-41.
15. Vermund SH, Fischer RD, Hoff R, et al. Preparing for HIV vaccine efficacy trials: partnerships and challenges. AIDS Res Hum Retroviruses 1993;10(suppl 1):127-32.
16. Hoff R, Barker L. Trial objectives and end points for measuring the efficacy of HIV vaccines. Infect Agents Dis 1995;4:95-101.
17. Rida W, Fast P, Hoff R, et al. Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:195-203.
18. US Congress, Office of Technology Assessment. Adverse reactions to HIV vaccines: medical, ethical, and legal issues. OTA-BP-H-163. Washington, DC: US Government Printing Office, 1995.
19. Sheon AR. Preventing discrimination against volunteers in preventive HIV vaccine efficacy trials: conference summary. AIDS Hum Retrovir 1995;11:1309-11.
20. Grady C. The search for an AIDS vaccine: ethical issues in the development and testing of a preventive HIV vaccine. Bloomington, IN: Indiana University Press, 1995:34-140.
21. Collins C. Sustaining support for domestic HIV vaccine research: social issues over the long haul of human trials. Monograph series occasional paper no. 2. San Francisco, CA: Center for AIDS Prevention Studies, University of California San Francisco, 1996.
22. AIDS Action Foundation. HIV preventive vaccines: social, ethical, and political considerations for domestic efficacy trials. Washington, DC: 1994.
23. Sheon AR, Wagner L, McElrath MJ, et al. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from the phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:519-26.
24. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr 1997;16:266-71.
25. Hodel D. HIV preventive vaccine efficacy trials in the US: overview of target communities concerns. AIDS Res Hum Retroviruses 1994;10(suppl 2):S255-6.
26. Turner CF, Sheon AR. Behavioral studies relevant to vaccine trial preparation: an introduction. AIDS Res Hum Retroviruses 1994;10 (suppl 2):S273-6.
27. Temoshok LR. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies. AIDS Res Hum Retroviruses 1994;10(suppl 2):S277-80.
28. Sugarman J. Toward achieving meaningful informed consent in AIDS vaccine trials with injection-drug users. AIDS Public Policy Journal 1994;9:167-72.
29. Lurie P, Bishaw M, Chesney M, et al. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA 1994;271:295-301.
30. Simes RJ, Tattersall MHN, Coates AS, et al. Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. BMJ 1986;293:1065-8.
31. Tymchuk AJ, Ouslander JG, Rader N. Informing the elderly: a comparison of four methods. J Am Geriatr Soc 1986;34:818-22.
32. Young DR, Hooker DT, Freeberg FE. Informed consent documents: increasing comprehension by reducing reading level. IRB 1990;May-June:1-5.
33. Peterson BT, Clancy SJ, Champion K, et al. Improving readability of consent forms: what the computers don't tell you. IRB 1992;November-December:6-8.
34. Muss HB, White DR, Michielutte R, et al. Written informed consent in patients with breast cancer. Cancer 1979;43:1549-56.
35. Levine RJ. More on making consent forms readable [editorial]. IRB 1982;January-February:8-9.
36. Meisel A. More on making consent forms readable [editorial]. IRB 1982;January-February:9.
37. Morrow G, Gootnick J, Schmale A. A simple technique for increasing cancer patients' knowledge of informed consent to treatment. Cancer 1978;42:793-9.
38. Based on analysis by RightWriter [computer program]. Version 3.1. RightSoft, Inc., 1989.
39. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
40. Harrison K, Vlahav D, Jones K, et al. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. JAIDS 1995;10:386-90.
41. Silva MC, Sorrell JM. Enhancing comprehension of information for informed consent: a review of empirical research. IRB 1988;January-February:1-5.
42. Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001;183:1343-52.
43. Barbour GL, Blumenkrantz MJ. Videotape aids informed consent decision. JAMA 1978;240:2741-2.